Lars Ynddal

Summary

Affiliation: Novo Nordisk A/S
Country: Denmark

Publications

  1. ncbi On-line turbulent-flow chromatography-high-performance liquid chromatography-mass spectrometry for fast sample preparation and quantitation
    Lars Ynddal
    Department of Drug Metabolism, Research and Development, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Maaloev, Denmark
    J Chromatogr A 1020:59-67. 2003
  2. ncbi Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo
    Per Sauerberg
    Novo Nordisk A S, Diabetes Research Unit, Novo Nordisk Park, 2760 Måløv, Denmark
    J Med Chem 50:1495-503. 2007
  3. ncbi New beta-alanine derivatives are orally available glucagon receptor antagonists
    Jesper Lau
    Protein Engineering, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Med Chem 50:113-28. 2007
  4. ncbi Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity
    Per Sauerberg
    Novo Nordisk A S, Novo Nordisk Park E9 2 02, 2760 Måløv, Denmark
    J Med Chem 45:789-804. 2002
  5. ncbi Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo
    Per Sauerberg
    Per Sauerberg, Novo Nordisk A S, Novo Nordisk Park, 2760 Måløv, Denmark
    J Med Chem 46:4883-94. 2003
  6. ncbi Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template
    John P Mogensen
    Novo Nordisk A S, Novo Nordisk Park, 2760 Måløv, Denmark
    Bioorg Med Chem Lett 13:257-60. 2003
  7. ncbi Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide
    Peter Madsen
    Department of Medicinal Chemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Med Chem 45:5755-75. 2002
  8. ncbi 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells
    Flemming E Nielsen
    Novo Nordisk Research and Development, Novo Nordisk Park, , Denmark
    J Med Chem 45:4171-87. 2002
  9. ncbi Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties
    Peter Madsen
    Novo Nordisk A S, Novo Nordisk Park, DK 2760 Maaloev, Denmark
    J Med Chem 52:2989-3000. 2009
  10. ncbi New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells
    Flemming E Nielsen
    Novo Nordisk Research and Development, Novo Nordisk Park, , Denmark
    J Med Chem 49:4127-39. 2006

Collaborators

Detail Information

Publications10

  1. ncbi On-line turbulent-flow chromatography-high-performance liquid chromatography-mass spectrometry for fast sample preparation and quantitation
    Lars Ynddal
    Department of Drug Metabolism, Research and Development, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Maaloev, Denmark
    J Chromatogr A 1020:59-67. 2003
    ..The detector response was quadratic and the dynamic range was estimated to be 0.5-100 ng/ml plasma or 12.5 pg to 2.50 ng injected into the system...
  2. ncbi Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo
    Per Sauerberg
    Novo Nordisk A S, Diabetes Research Unit, Novo Nordisk Park, 2760 Måløv, Denmark
    J Med Chem 50:1495-503. 2007
    ..These data suggest that selective PPARdelta agonists have the potential to become a novel treatment of dyslipidemia...
  3. ncbi New beta-alanine derivatives are orally available glucagon receptor antagonists
    Jesper Lau
    Protein Engineering, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Med Chem 50:113-28. 2007
    ..This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model...
  4. ncbi Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity
    Per Sauerberg
    Novo Nordisk A S, Novo Nordisk Park E9 2 02, 2760 Måløv, Denmark
    J Med Chem 45:789-804. 2002
    ..Investigations of the pharmacokinetics of selected compounds suggested that extended drug exposure improved the in vivo activity of in vitro active compounds...
  5. ncbi Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo
    Per Sauerberg
    Per Sauerberg, Novo Nordisk A S, Novo Nordisk Park, 2760 Måløv, Denmark
    J Med Chem 46:4883-94. 2003
    ..X-ray crystal structure and modeling experiments suggested that the dimers interacted with the AF-2 helix as well as with amino acid residues in the lipophilic pocket close to the receptor surface...
  6. ncbi Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template
    John P Mogensen
    Novo Nordisk A S, Novo Nordisk Park, 2760 Måløv, Denmark
    Bioorg Med Chem Lett 13:257-60. 2003
    ..These compounds could become useful tools for studying the combined biological effects of PPARalpha/gamma/delta activation...
  7. ncbi Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide
    Peter Madsen
    Department of Medicinal Chemistry, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Måløv, Denmark
    J Med Chem 45:5755-75. 2002
    ..This compound was orally available in dogs (F(po) = 15%) and was active in a glucagon-challenged rat model of hyperglucagonemia and hyperglycemia...
  8. ncbi 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells
    Flemming E Nielsen
    Novo Nordisk Research and Development, Novo Nordisk Park, , Denmark
    J Med Chem 45:4171-87. 2002
    ....
  9. ncbi Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties
    Peter Madsen
    Novo Nordisk A S, Novo Nordisk Park, DK 2760 Maaloev, Denmark
    J Med Chem 52:2989-3000. 2009
    ..Further, high plasma exposures and a long plasma half-life (5.2 h) were obtained...
  10. ncbi New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells
    Flemming E Nielsen
    Novo Nordisk Research and Development, Novo Nordisk Park, , Denmark
    J Med Chem 49:4127-39. 2006
    ..0 mg/kg). Structural modifications of this series of K(ATP) channel openers have provided compounds with promising pharmacokinetic properties indicating that brief periods of beta cell rest can be achieved...